Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Elisa Diral, MD, Philipp Le Coutre, MD, Enrico Marco Gottardi, Chiara Elena, MD, Micaela Bergamaschi, MD, Sarit Assouline, MD, Eros Di Bona, MD, Jessica Petiti, PhD, Fabio Stagno, MD, Alessandra Iurlo, MD PhD, Dong-Wook Kim, Alessandra Pirola, MSc, Maria Luisa Bonanomi, Patrizia Crivori, PhD, Rocco Piazza, MD PhD, Carmen Fava, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 29.

https://doi.org/10.1182/blood-2019-125226

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Blood (2018) 132 (Supplement 1): 460.

https://doi.org/10.1182/blood-2018-99-112119

Published: 2018

Journal Articles

Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months

Blood (2018) 132 (Supplement 1): 461.

https://doi.org/10.1182/blood-2018-99-112982

Published: 2018

Journal Articles

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Philipp G. Hemmati, MD, Theis Terwey, MD, Il-Kang Na, MD, Christian Jehn, MD, Lam G. Vuong, PhD, Philipp le Coutre, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2015) 126 (23): 2012.

https://doi.org/10.1182/blood.V126.23.2012.2012

Published: 2015

Journal Articles

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Blood (2015) 126 (23): 2775.

https://doi.org/10.1182/blood.V126.23.2775.2775

Published: 2015

Journal Articles

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Jaspal Kaeda, PhD FRCPath, Simone Bonecker, Frauke Ringel, Michaela Schwarz, Bernd Dörken, Ilana Zalcberg, Philipp Le Coutre, MD

Blood (2015) 126 (23): 2784.

https://doi.org/10.1182/blood.V126.23.2784.2784

Published: 2015

Journal Articles

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

Renato Tavares, MD, Giuseppe A. Palumbo, MD, Philipp Le Coutre, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Jose Grasa Ullrich, MD, Massimo Breccia, MD, David Brittain, MD, Lynda Foltz, MD FRCP, Martin Griesshammer, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Pilar Giraldo, MD PhD, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, MD MBA, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2799.

https://doi.org/10.1182/blood.V126.23.2799.2799

Published: 2015

Journal Articles

The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis

Blood (2014) 124 (21): 813.

https://doi.org/10.1182/blood.V124.21.813.813

Published: 2014

Journal Articles

MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines

Jaspal S Kaeda, PhD, Simone Bonecker, Iris von Wunsch-Rolshoven, Frauke Ringel, PhD, Michaela Schwarz, Bernd Dörken, MD, Ilana Zalcberg, Philipp le Coutre, MD

Blood (2014) 124 (21): 4533.

https://doi.org/10.1182/blood.V124.21.4533.4533

Published: 2014

Journal Articles

The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program

Giuseppe Saglio, MD, Philipp le Coutre, MD, Jorge E. Cortes, MD, Jiří Mayer, MD, Philip A. Rowlings, MBBS FRACP FRCPA MS, Francois-Xavier Mahon, MD PhD, Glenn S. Kroog, MD, Kyna Gooden, PhD MPH, Milayna Subar, MD, Jeanette A. Preston, MD MPH, Neil P. Shah, MD PhD

Blood (2014) 124 (21): 4534.

https://doi.org/10.1182/blood.V124.21.4534.4534

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Frequency of a Highly Polymorphic Variant, S36N GFI1 , Is Increased in CML Patients

Jaspal S Kaeda, PhD, Leila Amini, BSc, Concetta Quintarelli, PhD, Iris von Wunsch-Rolshoven, Frauke Ringel, PhD, Michaela Schwarz, MD, Fabrizio Pane, MD, Bernd Dörken, MD, Philipp le Coutre, MD

Blood (2014) 124 (21): 3157.

https://doi.org/10.1182/blood.V124.21.3157.3157

Published: 2014

Journal Articles

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Richard A. Larson, Dong-Wook Kim, MD PhD, Surapol Issaragrilsil, MD, Philipp le Coutre, MD, Pedro Enrique Dorlhiac Llacer, Gabriel Etienne, MD PhD, Richard E. Clark, MD, Ian Flinn, Hirohisa Nakamae, Andreas Hochhaus, MD, Giuseppe Saglio, MD, Hagop M. Kantarjian, Breanne Donohue, PharmD, Weiping Deng, PhD, Hans D. Menssen, MD PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4541.

https://doi.org/10.1182/blood.V124.21.4541.4541

Published: 2014

Journal Articles

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Il-Kang Na, MD, Philipp le Coutre, MD, Christian F. Jehn, MD, Lam G. Vuong, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2014) 124 (21): 2569.

https://doi.org/10.1182/blood.V124.21.2569.2569

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Martin Griesshammer, MD, Alessandro M. Vannucchi, MD, Philipp le Coutre, MD, Renato S Tavares, MD, Haifa Kathrin Al-Ali, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, MD MBA, Jagannath Ghosh, Bruno Martino, MD

Blood (2014) 124 (21): 1859.

https://doi.org/10.1182/blood.V124.21.1859.1859

Published: 2014

NARROW

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis

MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines

The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Frequency of a Highly Polymorphic Variant, S36N GFI1 , Is Increased in CML Patients

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only